Answers are grounded in this paper and cite their sources.
We have recently reported that lymphocyte activation gene-3 (LAG-3,CD223) mediates the alternative, IFNα-deficient activation of plasmacytoid dendritic cells (pDCs) at tumor sites. Our findings define a novel tumor-driven strategy that promotes immunosuppression by pDCs, and we have provided more detailed information regarding the immunomodulatory role of of LAG-3. The translational relevance of our results for the treatment of tumors and autoimmune diseases is discussed herein.
No takes yet. Share an insight, caveat, or question.
Castelli et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: